357405-75-5

Usage

Uses

Used in Pharmaceutical Industry:
4-bromo-2,5-difluorobenzaldehyde is used as a key intermediate for the synthesis of various pharmaceuticals. Its unique structural features and reactivity allow for the development of novel and efficient synthetic routes, leading to the creation of new drug candidates with improved therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 4-bromo-2,5-difluorobenzaldehyde serves as a building block for the preparation of various agrochemicals. Its versatile reactivity enables the synthesis of new compounds with enhanced pesticidal or herbicidal activities, contributing to more effective crop protection.
Used in Advanced Materials:
4-bromo-2,5-difluorobenzaldehyde is utilized in the development of advanced materials, such as polymers, dyes, and sensors. Its electron-withdrawing and electron-donating groups facilitate the design of materials with tailored properties, such as improved conductivity, selectivity, or sensitivity, for various applications.
Used in Synthetic Chemistry Research:
As a versatile intermediate, 4-bromo-2,5-difluorobenzaldehyde is employed in synthetic chemistry research to explore novel synthetic routes and develop new methodologies. Its unique reactivity allows chemists to investigate new reactions and mechanisms, ultimately contributing to the advancement of synthetic chemistry.

Upstream product

• 109-72-8 n-butyllithium 
• 327-51-5 1,4-dibromo-2,5-difluorobenzene 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1341660-62-5 1-bromo-4-(chloromethyl)-2,5-difluoro-benzene 
• 486460-26-8 (4-bromo-2,5-difluorophenyl)methanol 

Relevant academic research and scientific papers

Ternary Polymer Solar Cells Facilitating Improved Efficiency and Stability

The use of a ternary active layer offers a promising approach to enhance the power conversion efficiency (PCE) of polymer solar cells (PSCs) via simply incorporating a third component. Here, a ternary PSC with improved efficiency and stability facilitated by a new small molecule IBC-F is demonstrated. Even though the PBDB-T:IBC-F-based device gives an extremely low PCE of only 0.21%, a remarkable PCE of 15.06% can be realized in the ternary device based on PBDB-T:IE4F-S:IBC-F with 20% IBC-F, which is ≈10% greater than that (PCE = 13.70%) of the control binary device based on PBDB-T:IE4F-S. The improvement in the device performance of the ternary PSC is mainly attributed to the enhancement of fill factor, which is due to the improved charge dissociation and extraction, suppressed bimolecular and trap-assisted recombination, longer charge-carrier lifetime, and enhanced intermolecular interactions for preferential face-on orientation. Additionally, the ternary device with 20% IBC-F shows better thermal and photoinduced stability over the control binary device. This work provides a new angle to develop the third components for building ternary PSCs with enhanced photovoltaic performance and stability for practical applications.

Process Development Overcomes a Challenging Pd-Catalyzed C-N Coupling for the Synthesis of RORc Inhibitor GDC-0022

Process development for a multi-kilogram-scale synthesis of GDC-0022, an inhibitor of retinoic acid receptor-related orphan receptor γ(RORc), is described. Delivery of the active pharmaceutical ingredient (API) relied on diastereoselective preparation of a six-membered sultam building block, as well as execution of its benzylation under heterogeneous conditions. Investigation and optimization of a challenging late-stage palladium-catalyzed C-N coupling of a bicyclic amine were likewise central to synthetic efforts. Understanding of this key reaction, as well as the development of API salt forms and isolations, ultimately enabled a successful reaction at 8.0 kg scale, utilizing 1.0 mol % XantPhos-Pd-G2 as precatalyst and, in turn, preparation of >5.0 kg of GDC-0022 tosylate salt for preclinical needs.

4-AMINO-6-(4-SUBSTITUTED-PHENYL)-PICOLINATES AND 6-AMINO-2-(4-SUBSTITUTED-PHENYL)-PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES

Provided herein are 4-amino-6-(4-substituted-phenyl)-picolinic acids and their derivatives, and 6-amino-2-(4-substituted-phenyl)-pyrimidine-4-carboxylic acids and their derivatives, compositions comprising the acids and their derivatives, and methods of use thereof as herbicides.

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

PIPERIDINYL- SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS

Compounds of Formula I: and pharmaceutically acceptable salts thereof, in which X1, X2, R3, R4, R5, Rx, R7, R9, R10 and n have the meanings given in the specification, are modulators of GPR119 and are useful in the treatment or prevention of diseases such as such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.

17α-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C17,20-lyase inhibitors.

Imidazole Substituted Pyrimidines

A compound of formula (I) wherein R1 is hydrogen or fluoro; R2 and R3 are independently selected from hydrogen or methyl, or a pharmaceutically acceptable salt thereof; pharmaceutical formulations containing said compound; the use of said compound in therapy; the use for the treatment of conditions associated with glycogen synthase kinase-3 related disorders, such as Alzheimer's disease, as well as methods of treatment of said disorders, comprising administering to subjects in need of such treatment, a therapeutically effective amount of said compound.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

Novel use of phenylheteroakylamine derivatives

There is disclosed the use of a compound of formula (I) wherein R1, R2, X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts, enantiomers or racemates thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial. Certain novel compounds of formula (Ia) and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof are disclosed; together with processes for their preparation, compositions containing them and their use in therapy. The compounds of formulae (I) and (Ia) are inhibitors of the enzyme nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease.